Nanoparticle-based biosensors for detection of extracellular vesicles in liquid biopsies

Martín-Gracia, Beatriz; Martín-Barreiro, Alba; Cuestas-Ayllon, Carlos; Grazú, Valeria; Linē, Aija; Llorente, Alicia; Fuente, Jesús M. de la; Moros, María

doi:10.1039/d0tb00861c

Cited by 42 publications

(35 citation statements)

References 227 publications

(242 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Different types of target recognition molecules can be used, including antibodies, peptides, lectins, cholesterol anchors, and aptamers. Recently, over forty reports of NP-based sensors for SEVs were comprehensively reviewed and compared [ 36 ]. The sensitivity (limit of detection, LOD) of these sensors ranged from 10 2 to 10 9 vesicles per mL of solution.…”

Section: Discussionmentioning

confidence: 99%

AuNP Aptasensor for Hodgkin Lymphoma Monitoring

Slyusarenko

Shalaev²,

Valitova³

et al. 2022

Biosensors

View full text Add to dashboard Cite

A liquid biopsy based on circulating small extracellular vesicles (SEVs) has not yet been used in routine clinical practice due to the lack of reliable analytic technologies. Recent studies have demonstrated the great diagnostic potential of nanozyme-based systems for the detection of SEV markers. Here, we hypothesize that CD30-positive Hodgkin and Reed–Sternberg (HRS) cells secrete CD30 + SEVs; therefore, the relative amount of circulating CD30 + SEVs might reflect classical forms of Hodgkin lymphoma (cHL) activity and can be measured by using a nanozyme-based technique. A AuNP aptasensor analytics system was created using aurum nanoparticles (AuNPs) with peroxidase activity. Sensing was mediated by competing properties of DNA aptamers to attach onto surface of AuNPs inhibiting their enzymatic activity and to bind specific markers on SEVs surface. An enzymatic activity of AuNPs was evaluated through the color reaction. The study included characterization of the components of the analytic system and its functionality using transmission and scanning electron microscopy, nanoparticle tracking analysis (NTA), dynamic light scattering (DLS), and spectrophotometry. AuNP aptasensor analytics were optimized to quantify plasma CD30 + SEVs. The developed method allowed us to differentiate healthy donors and cHL patients. The results of the CD30 + SEV quantification in the plasma of cHL patients were compared with the results of disease activity assessment by positron emission tomography/computed tomography (PET-CT) scanning, revealing a strong positive correlation. Moreover, two cycles of chemotherapy resulted in a statistically significant decrease in CD30 + SEVs in the plasma of cHL patients. The proposed AuNP aptasensor system presents a promising new approach for monitoring cHL patients and can be modified for the diagnostic testing of other diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

AuNP Aptasensor for Hodgkin Lymphoma Monitoring

Slyusarenko

Shalaev²,

Valitova³

et al. 2022

Biosensors

View full text Add to dashboard Cite

show abstract

“…Thus, this biosensor quantified changes in the number of cancer cell-specific EVs from human blood at the sensor surface upon binding to the antibodies within 1 h. These studies demonstrate the importance of developing advanced biosensors to replace conventional methods that are time-consuming and multiple handling steps. Several excellent reviews have also comprehensively discussed the applications, strengths, and drawbacks of the nanomaterial-based biosensors for detecting EVs 98 , 107 , 108 . After those nanoplatforms identifying and isolating EVs, EV-derived biomarkers can be profiled by conventional methods.…”

Section: The Biological and Pathophysiological Characteristics Of Evsmentioning

confidence: 99%

Harnessing Tissue-derived Extracellular Vesicles for Osteoarthritis Theranostics

Yin¹,

Ni²,

Witherel³

et al. 2022

Theranostics

View full text Add to dashboard Cite

Osteoarthritis (OA) is a prevalent chronic whole-joint disease characterized by low-grade systemic inflammation, degeneration of joint-related tissues such as articular cartilage, and alteration of bone structures that can eventually lead to disability. Emerging evidence has indicated that synovium or articular cartilage-secreted extracellular vesicles (EVs) contribute to OA pathogenesis and physiology, including transporting and enhancing the production of inflammatory mediators and cartilage degrading proteinases. Bioactive components of EVs are known to play a role in OA include microRNA, long non-coding RNA, and proteins. Thus, OA tissues-derived EVs can be used in combination with advanced nanomaterial-based biosensors for the diagnostic assessment of OA progression. Alternatively, mesenchymal stem cell- or platelet-rich plasma-derived EVs (MSC-EVs or PRP-EVs) have high therapeutic value for treating OA, such as suppressing the inflammatory immune microenvironment, which is often enriched by pro-inflammatory immune cells and cytokines that reduce chondrocytes apoptosis. Moreover, those EVs can be modified or incorporated into biomaterials for enhanced targeting and prolonged retention to treat OA effectively. In this review, we explore recently reported OA-related pathological biomarkers from OA joint tissue-derived EVs and discuss the possibility of current biosensors for detecting EVs and EV-related OA biomarkers. We summarize the applications of MSC-EVs and PRP-EVs and discuss their limitations for cartilage regeneration and alleviating OA symptoms. Additionally, we identify advanced therapeutic strategies, including engineered EVs and applying biomaterials to increase the efficacy of EV-based OA therapies. Finally, we provide our perspective on the future of EV-related diagnosis and therapeutic potential for OA treatment.

show abstract

“…Nanoparticles with optical, magnetic and mechanical properties are widely harnessed in biosensor and imaging. [ 39 ] By covalent…”

Section: Nanoparticle‐based Biosensormentioning

confidence: 99%

DNA‐Based Architectures for in situ Target Biomolecule Analysis in Confined Nano‐space^†

Huang

Yin

et al. 2021

Chin. J. Chem.

View full text Add to dashboard Cite

In situ target biomolecule analysis is of great significance for real‐time monitoring and regulation of endogenous biomarkers and elementary biomolecules in vivo. Gratifyingly, the rapid evolution of structural DNA nanotechnology during past decades has established an appealing toolbox for biological analysis and medical detection. The modulated self‐assembly and underlying canonical Watson‐Crick base‐pairing rules provide possibilities for accurate controlling of the topologies and functions of obtained nanomaterials. The probes composed of diverse DNA nanostructures and DNA‐nanoparticle complexes can create a confined space, which increases target accessibility and improves probe stability, sensitivity and specificity. In this minireview, we retrospect the research progress of in‐situ biomolecular analysis based on DNA nanostructures for intracellular and in vivo biosensors in confined space. The characteristics of distinct DNA nanomaterials are first introduced, and then the fundamentals of biosensing process of designed DNA nanostructures are emphasized. Moreover, we elucidate our perspective over the challenges of this field and discuss the potential directions of this kind of application‐oriented fabrication technique.

show abstract

Nanoparticle-based biosensors for detection of extracellular vesicles in liquid biopsies

Abstract:
Selecting the appropriate nanoparticle, functionalization chemistry and sensing methodology can speed up the translation of liquid biopsies into the clinic.

Cited by 42 publications

References 227 publications

AuNP Aptasensor for Hodgkin Lymphoma Monitoring

AuNP Aptasensor for Hodgkin Lymphoma Monitoring

Harnessing Tissue-derived Extracellular Vesicles for Osteoarthritis Theranostics

DNA‐Based Architectures for in situ Target Biomolecule Analysis in Confined Nano‐space^†

Contact Info

Product

Resources

About

Nanoparticle-based biosensors for detection of extracellular vesicles in liquid biopsies

Abstract: Selecting the appropriate nanoparticle, functionalization chemistry and sensing methodology can speed up the translation of liquid biopsies into the clinic.

Cited by 42 publications

References 227 publications

AuNP Aptasensor for Hodgkin Lymphoma Monitoring

AuNP Aptasensor for Hodgkin Lymphoma Monitoring

Harnessing Tissue-derived Extracellular Vesicles for Osteoarthritis Theranostics

DNA‐Based Architectures for in situ Target Biomolecule Analysis in Confined Nano‐space†

Contact Info

Product

Resources

About

Abstract:
Selecting the appropriate nanoparticle, functionalization chemistry and sensing methodology can speed up the translation of liquid biopsies into the clinic.

DNA‐Based Architectures for in situ Target Biomolecule Analysis in Confined Nano‐space^†